Recent advances of highly selective CDK4/6 inhibitors in breast cancer - Wikidata - wikimedia - TriplyDB

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

http://www.wikidata.org/entity/Q33602076

about

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas DACH1 suppresses breast cancer as a negative regulator of CD44.Abemaciclib: First Global Approval.Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer.Breast cancer: The translation of big genomic data to cancer precision medicine.Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.Identification of the potential crucial genes in invasive ductal carcinoma using bioinformatics analysis.The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer.Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Recent Advances in the Treatment of Breast Cancer.[Role of PD 0332991 on the Proliferation and Apoptosis of Vascular Endothelial Cells].Profile of abemaciclib and its potential in the treatment of breast cancer Mechanisms for estrogen receptor expression in human cancer Organoid technology and applications in cancer research Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

P2860

Q33815063-50ECC35C-9A6E-40AD-8E2C-821EBFDDDB9B Q33849252-26AB981D-A044-4FCE-A682-976E05C44274 Q43280771-A394A6A7-C975-48AC-B9F7-94FD1A117A6E Q43281043-D34787E2-9BD5-45F2-9607-CBA562D91804 Q44420270-CE0EDA2A-3A21-428D-8740-5BEB748ADAA4 Q45943221-738C924A-5D2A-4C49-BD0C-7C2B8AFFB40F Q47102212-3E6913AD-824F-41FD-99CA-CB00EA688882 Q47144472-14CB0F8E-CE7E-4921-8642-D95E7DB16646 Q47260412-8533984A-8882-42E1-A542-A5143A04001A Q47823987-C42DFF02-5D62-4F69-BBB2-C82DAF36DF38 Q49177338-7DB01399-D533-4232-AE5F-3B20049B9633 Q49689467-011414A9-8D0F-4F45-97AB-5A4B4402461D Q50231197-08434C08-D0D0-4FE8-A3D2-7E3DDCA307F6 Q54109356-DD1E7BFB-D698-4220-A401-0BF6245CA2A2 Q54976480-187D3A7C-9854-4495-873C-09D4818020D6 Q55241008-7412CC24-56CA-448D-92E6-7C3D298CEA56 Q55310990-692671E3-A0FC-48C0-BF02-8F51BF141144 Q55353691-9AD9AE6B-84B6-4358-909B-F63837B24739 Q55464355-DBF7CD98-2921-4465-83F1-FD9F6DBE5FB0 Q57107448-ACEC4D42-009C-472F-BBC7-054D321FE8C3 Q58718563-1C4E53AD-2B5E-4BD5-B9CD-AE12536459F5 Q58737628-20B1A772-623A-4890-9E7F-BE5E6D8440F9 Q58799791-59B70B2A-79B6-43AC-8A5A-791BF19F9A33

P2860

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

http://www.wikidata.org/entity/Q33602076

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@ast

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@en

type

label

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@ast

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@en

prefLabel

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@ast

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@en

P1433

Q33602076-1AC48A57-702B-4203-B215-BE3789925CE4

P1476

Q33602076-DAB86054-0267-4143-849F-6B6FD11851F7

P2093

Q33602076-0876F154-8693-4595-B867-EACA7E62D914

Q33602076-67239B70-78A5-42B9-B587-E750E73E8274

Q33602076-CE972AF3-BD9E-4A59-AD6A-A78B66136FB0

Q33602076-DAEB6EBE-8105-4BC2-B090-66BD348CFA7D

Q33602076-E876A369-ADEB-4F97-91F4-F67FD4E70DD9

Q33602076-E8DFFCF2-E900-4E1B-B599-AC31B9690D9B

Q33602076-F0BC29B3-2240-4DD5-8A73-79F86C9384B0

P275

Q33602076-E430A29F-BE4C-44DC-8221-4678894487DA

P2860

Q33602076-076D22FE-5270-4D07-9095-D57FD50F5E7E

Q33602076-091FDF09-C4C9-404E-8E22-EC3753EFFD21

Q33602076-0C5149C4-51B4-4697-BD5D-BF8DC65910D1

Q33602076-0DE9438A-1451-4A7C-9717-F1B6ABF385F7

Q33602076-0FF3160C-494F-4B84-BC86-E70ADAAC63EA

Q33602076-19C965A6-D186-41BD-9A6B-F59D6884DABB

Q33602076-1D9DF84D-4F77-4C8F-9C75-9E2EC5D9D06D

Q33602076-1E8B4F6B-F325-489F-96B9-33CF6168E5F7

Q33602076-224E949B-7FFB-4CA3-96E1-D2AC6403C857

Q33602076-24504654-4219-4EB4-996B-B435948200D7

P2888

Q33602076-6A142517-940B-4765-A814-116B51510688

P304

Q33602076-11BA4B87-28CE-4A2F-B675-3DD5260EBAD9

P31

Q33602076-28FC36FE-F480-4EDF-928E-41998C2B0794

Q33602076-5F0B9B75-DD75-4B81-A29F-BB5D6E0C79F0

P356

Q33602076-F7C5A349-9FCA-4F46-8523-50C8071B52E9

P433

Q33602076-15D94E3B-B959-4079-9D88-3331CDE7826C

P478

Q33602076-417D3C07-60F9-4ABB-B343-D73F81188CC8

P5008

Q33602076-43E33485-3A70-4D2B-B684-FAA14C8DD60C

P577

Q33602076-00DB1B42-C308-48ED-97E6-79A3CF00E7A6

P6179

Q33602076-C0417F3E-AE10-4EEE-960C-A725E2FACDA5

P698

Q33602076-46014490-8093-4363-BEE7-5B508BE741E2

P921

Q33602076-2B64898C-ECA4-4E6A-AE94-19436EF1A735

Q33602076-73A2D397-802F-41E0-9395-37EDA83E20D5

Q33602076-7FC52323-3FD9-459D-B3B6-E12BCB379FC4

Q33602076-9918A940-BFCF-41B2-8570-061F94683355

Q33602076-AF9ABDC0-B73B-43C0-93A9-A528141A48BC

Q33602076-EE20F661-B74B-43EB-B3B3-ACD266ED1D54

P932

Q33602076-B9B4DD2E-5A04-4C91-8AAD-165149A8E35D

P356

S13045-017-0467-2

P1433

Journal of Hematology & Oncology

P1476

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

@en

P2093

Hanxiao Xu

http://www.w3.org/2001/XMLSchema#string

Kongming Wu

http://www.w3.org/2001/XMLSchema#string

Qian Liu

http://www.w3.org/2001/XMLSchema#string

Richard G Pestell

http://www.w3.org/2001/XMLSchema#string

Shengnan Yu

http://www.w3.org/2001/XMLSchema#string

Sridhar Mani

http://www.w3.org/2001/XMLSchema#string

Xun Yuan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Cell cycle, CDKs and cancer: a changing paradigm

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

FoxM1, a critical regulator of oxidative stress during oncogenesis

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Targeting CDK4/6 in patients with cancer

P2888

s13045-017-0467-2

P304

97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-017-0467-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084955176

http://www.w3.org/2001/XMLSchema#string

P698

28438180

http://www.w3.org/2001/XMLSchema#string

P921

breast neoplasm

neoplasm proteins

cell cycle proteins

P932

5404666

http://www.w3.org/2001/XMLSchema#string